Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.76

-2.1%

4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2581)	9/10/2009 2:00:26 PM
From: Jibacoa	Read Replies (1) of 3722

CYCC was up 22.77% at its intraday H, but is up only 12.87% at present.<g> bigcharts.marketwatch.com It's CEO will be presenting tthis afternoon at the Rodman & Renshaw 11th Annual Healthcare Conference in N.Y. CYCC has Sapacitabine, a cell cycle modulating nucleoside analog, is in PII for acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer and in PI in combination with seliciclib. Seliciclib, is in PII for lung and nasopharyngeal Cas. CYCC also has CYC116, an Aurora kinase and VEGFR2 inhibitor,which is in PI for solid tumors, and its ALIGN Pharmaceuticals subsidiary markets in the U.S. Xclair Cream for radiation dermatitis, Numoisyn Liquid and Numoisyn Lozenges for xerostomia. CYCC has 4 consecutive Qs of higher revenues and has also been trimming its losses. The loss for the current YR. is projected around $0.90 vs. the $1.98 loss in 2008 The stock needs to close above the resistance at $1.25 before it can re-test its Jun 15 H at $1.66 <g> bigcharts.marketwatch.com But keep an eye on CYCC, it has no significant LTD and less than 25M shrs out. With some good news it has plenty of room to run.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next